- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT06175000
Obinutuzumabe de manutenção no tratamento de pacientes com linfoma do sistema nervoso central que obtiveram uma resposta completa ou parcial
Obinutuzumabe de manutenção para linfoma primário do sistema nervoso central com resposta completa ou parcial
This randomized phase II trial studies how well obinutuzumab works as maintenance treatment in patients with central nervous system lymphoma who have achieved the disappearance of all signs of cancer in response to treatment (complete response) or a decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment (partial response). Immunotherapy with obinutuzumab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread.
Visão geral do estudo
Status
Intervenção / Tratamento
Descrição detalhada
PRIMARY OBJECTIVE:
I. To determine the effect of maintenance obinutuzumab on duration of response (partial response [PR] or complete response [CR]) in patients with CD20+ B-cell primary central nervous system lymphoma (PCNSL) who attain PR or CR to first-line treatment with high-dose methotrexate-based chemotherapy.
SECONDARY OBJECTIVES:
I. To evaluate overall survival after PR or CR (overall survival [OS]-PRCR). II. To evaluate neurocognitive function, quality of life, and neuroimaging as indicators of neurotoxicity.
III. Progression-free survival (PFS) and overall survival (OS) will be calculated.
OUTLINE: Patients are randomized to 1 of 2 treatment arms.
ARM I (MAINTENANCE THERAPY): Patients receive obinutuzumab intravenously (IV) on days 1 and 2 for the first cycle, and on day 1 for the subsequent cycles. Cycles repeat every 60 days for 2 years in the absence of disease progression or unacceptable toxicity.
ARM II (OBSERVATION): Patients undergo observation for a total of 2 years.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Fase 2
Contactos e Locais
Contato de estudo
- Nome: Tiffany Gervasi-Follmar
- Número de telefone: 503-216-1023
- E-mail: tiffany.gervasi-follmar@providence.org
Estude backup de contato
- Nome: Holly Marino
- Número de telefone: 503-216-1034
- E-mail: holly.marino@providence.org
Locais de estudo
-
-
New York
-
New York, New York, Estados Unidos, 10065
- Recrutamento
- Memorial Sloan Kettering Cancer Center
-
Contato:
- Lindey Myers
- Número de telefone: 917-453-2968
- E-mail: myersl1@mskcc.org
-
Investigador principal:
- Christian Grommes, MD
-
-
Ohio
-
Cleveland, Ohio, Estados Unidos, 44195
- Retirado
- Cleveland Clinic
-
-
Oregon
-
Portland, Oregon, Estados Unidos, 97225
- Recrutamento
- Providence Health & Services; Providence Neurological Specialties
-
Investigador principal:
- Prakash Ambady, MD
-
Contato:
- Kai Darke
- Número de telefone: 503-216-0627
- E-mail: kai.darke@providence.org
-
Contato:
- Kimberly Perry
- Número de telefone: 971-231-8245
- E-mail: kimberly.perry2@providence.org
-
-
Pennsylvania
-
Hershey, Pennsylvania, Estados Unidos, 17033
- Recrutamento
- Pennsylvania State University
-
Investigador principal:
- Dawit Aregawi, MD
-
Contato:
- Micaiah Grien
- Número de telefone: 283063 717-531-0003
- E-mail: mgrien@pennstatehealth.psu.edu
-
Contato:
- Sara Craig
- Número de telefone: 285799 717-531-0003
- E-mail: scraig2@pennstatehealth.psu.edu
-
-
Vermont
-
Burlington, Vermont, Estados Unidos, 05405
- Recrutamento
- University of Vermont
-
Contato:
- Isza Parchini
- Número de telefone: 802-656-9447
- E-mail: isza.parchini@uvahealth.org
-
Contato:
- George Davis
- E-mail: george.davis@uvmhealth.org
-
Investigador principal:
- Alissa Thomas, MD
-
-
Virginia
-
Charlottesville, Virginia, Estados Unidos, 22903
- Recrutamento
- University of Virginia
-
Investigador principal:
- David Schiff, MD
-
Contato:
- Nija Desai
- Número de telefone: 434-982-6455
- E-mail: NND2A@uvahealth.org
-
Contato:
- Patrick Heffernan
- Número de telefone: 434-243-9508
- E-mail: YWW2NJ@uvahealth.org
-
-
Washington
-
Seattle, Washington, Estados Unidos, 98122
- Recrutamento
- Ivy Center for Advanced Brain Tumor Treatment; Swedish Neuroscience Institute
-
Contato:
- Nathan Hansen
- Número de telefone: 206-320-3542
- E-mail: nathan.hansen@swedish.org
-
Contato:
- Gary Brown
- Número de telefone: 206-320-2608
- E-mail: gary.brown@swedish.org
-
Investigador principal:
- Alipi Bomn, MD
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- CD20+ B-cell primary central nervous system lymphoma (PCNSL) confirmed at the time of diagnosis by histology, cytology, or immunocytochemistry from cerebrospinal fluid (CSF); diagnosis must be documented by pathology report.
- Must have undergone first-line treatment with a high-dose methotrexate-based chemotherapy regimen with or without brain radiotherapy; high-dose methotrexate is defined as >= 3 grams/m^2; methotrexate dose reduction for creatinine clearance < 100 ml/min is permitted
- Must be within 75 days of completion of first-line treatment regimen at the time of randomization; must have achieved objective response (PR or CR/unconfirmed complete response [CRu]) to first-line treatment
- Brain magnetic resonance imaging (MRI) documenting objective response must be obtained within 30 days before randomization
- If CSF was positive for lymphoma cells at diagnosis or during first-line treatment and/or a slit lamp examination was positive at diagnosis or during first-line treatment, then the CSF and vitreal studies must have been repeated and must have indicated CR; Note: CR requires complete disappearance of all enhancing abnormalities on gadolinium-enhanced MRI; if CSF was positive for lymphoma cells at diagnosis or during first-line treatment and/or slit lamp examination was positive at diagnosis or during first-line treatment, then the CSF and vitreal studies must have been repeated and must have indicated CR; for CRu, some patients will have a small but persistent enhancing abnormality on MRI related to biopsy or focal hemorrhage; it is often difficult to ascertain whether this represents a residual nidus of tumor or scar tissue; if the abnormality does not change or slowly involutes without therapy and corticosteroids, it is reasonable to categorize as a CRu; at the time CR/CRu is determined, the patient should not have used corticosteroids for at least two weeks
- Karnofsky performance status (KPS) >= 60; Eastern Cooperative Oncology Group (ECOG) 0, 1, or 2
- Signed informed consent form (ICF)
- Ability and willingness to comply with the requirements of the study protocol
- Total bilirubin < 3 x the upper limit of normal (ULN), ≤ 7 days before date of randomization
- Creatinine clearance > 30 mL/min (calculated according to institutional standards or using Cockcroft-Gault formula), ≤ 7 days before date of randomization
- Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≤ 5 x ULN, ≤7 days before date of randomization
- Platelet ≤ 75,000 cells/mm^3, ≤ 7 days before date of randomization
- Hemoglobin > 9 g/dL, ≤ 7 days before date of randomization
- Absolute neutrophil count > 1.5 x 10^3 cells/mm^3, ≤ 7 days before date of randomization
- Surgically sterile or agree to use effective contraception using an adequate measure of contraception such as oral contraceptives, intrauterine device, or barrier method of contraception in conjunction with spermicidal jelly while receiving obinutuzumab and >= 18 months after the last dose of obinutuzumab for women, and 180 days after the last dose of obinutuzumab for men
Exclusion Criteria:
- History of severe allergic or anaphylactic reactions to monoclonal antibody therapy
- Clinical evidence of extra-central nervous system (CNS) (systemic) non-Hodgkin lymphoma
- Known hypersensitivity to any of the study drugs
- History of other malignancy that could affect compliance with the protocol or interpretation of results
- Patients with a history of curatively treated basal or squamous cell carcinoma of the skin or in situ carcinoma of the cervix are generally eligible; patients with a malignancy that has been treated, but not with curative intent, will also be excluded, unless the malignancy has been in remission without treatment for >= 2 years prior to randomization
- Known active bacterial, viral, fungal, mycobacterial, or other infection (excluding fungal infections of nail beds) or any major episode of infection requiring treatment with IV antibiotics or hospitalization (related to the completion of the course of antibiotics) within 4 weeks prior to study randomization
- Major surgery within 4 weeks prior to study randomization
- Known infection with human immunodeficiency virus (HIV)
- Positive hepatitis serologies:
- Hepatitis B (HBV): patients with positive serology for hepatitis B defined as positivity for hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (anti-HBc); patients who are positive for anti-HBc may be considered for inclusion in the study on a case-by-case basis if they are hepatitis B viral deoxyribonucleic acid (DNA) negative and are willing to undergo ongoing HBV DNA testing by real-time polymerase chain reaction (PCR); patients with positive serology may be referred to a hepatologist or gastroenterologist for appropriate monitoring and management
- Hepatitis C (HCV): patients with positive hepatitis C serology unless HCV ribonucleic acid (RNA) is confirmed negative and may be considered for inclusion in the study on a case-by-case basis
- Women who are pregnant or lactating
- Vaccination with a live vaccine a minimum of 4 weeks prior to study randomization
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Solteiro
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Arm I (obinutuzumab
Patients receive obinutuzumab IV on days 1 and 2 for the first cycle, and on day 1 for the subsequent cycles, and on day 1 for the subsequent cycles. Cycles repeat every 60 days for 2 years in the absence of disease progression or unacceptable toxicity. |
Given IV
Outros nomes:
Ancillary studies to evaluate neurocognitive function at study entry and at 2 years after study entry. Ancillary studies to evaluate quality of life at study entry and at 2 years after study entry. |
|
Comparador Ativo: Arm II (observation)
Patients undergo observation for a total of 2 years. |
Ancillary studies to evaluate neurocognitive function at study entry and at 2 years after study entry. Ancillary studies to evaluate quality of life at study entry and at 2 years after study entry. |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Partial response (PR) or complete response (CR) duration
Prazo: From the date of brain magnetic resonance imaging (MRI) after completion of first-line treatment which confirms PR or CR, to disease progression or death, assessed up to 2 years
|
PR or CR duration will be assessed using Kaplan-Meier product limit estimates and compared between patients with maintenance versus without obinutuzumab maintenance using the log-rank test. In addition, the Cox proportional hazard model will be used to estimate hazard ratios. |
From the date of brain magnetic resonance imaging (MRI) after completion of first-line treatment which confirms PR or CR, to disease progression or death, assessed up to 2 years
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Overall survival (OS) after CR
Prazo: From the date of brain MRI after completion of first-line treatment which confirms PR or CR, to death, assessed up to 2 years
|
OS after PR or CR will be assessed using Kaplan-Meier product limit estimates and compared between patients with maintenance versus without obinutuzumab maintenance using the log-rank test. In addition, the Cox proportional hazard model will be used to estimate hazard ratios. |
From the date of brain MRI after completion of first-line treatment which confirms PR or CR, to death, assessed up to 2 years
|
|
Neurocognitive function - Wechsler Adult Intelligence Scale
Prazo: Up to 2 years
|
Will be measured by the Wechsler Adult Intelligence Scale. Scale range 0 to 16 Forward; 0 to 14 Backward. Higher the score means better outcome. Longitudinal data of neurocognitive function will be analyzed using a linear mixed model and toxicity indicators will be assessed using a chi-square or exact test. |
Up to 2 years
|
|
Quality of life (QOL) - European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Brain Neoplasm 20-item
Prazo: Up to 2 years
|
Will be measured by the European Organization for Research and Treatment of Cancer Quality of Life Brain Cancer Module-20 (EORTC QLQ-BN20) questionnaire. Scale 20 to 80 points. Higher score means worse outcome. Longitudinal data of QOL will be analyzed using a linear mixed model and toxicity indicators will be assessed using a chi-square or exact test. |
Up to 2 years
|
|
Progression free survival (PFS)
Prazo: From the start date of first-line primary central nervous system lymphoma (PCNSL) treatment to disease progression or death, assessed up to 2 years
|
PFS will be assessed using Kaplan-Meier product limit estimates and compared between patients with obinutuzumab maintenance versus without maintenance using the log-rank test. Longitudinal data of neurocognitive function and QOL will be analyzed using a linear mixed model and toxicity indicators will be assessed using a chi-square or exact test. |
From the start date of first-line primary central nervous system lymphoma (PCNSL) treatment to disease progression or death, assessed up to 2 years
|
|
Overall survival
Prazo: From the start date of first-line PCNSL treatment to death, assessed up to 2 years.
|
OS will be assessed using Kaplan-Meier product limit estimates and compared between patients with obinutuzumab maintenance versus without maintenance using the log-rank test. Longitudinal data of neurocognitive function and QOL will be analyzed using a linear mixed model and toxicity indicators will be assessed using a chi-square or exact test. |
From the start date of first-line PCNSL treatment to death, assessed up to 2 years.
|
|
Neurocognitive function - Hopkins Verbal Learning Test-Revised
Prazo: Up to 2 years
|
Will be measured by the Hopkins Verbal Learning Test-Revised. Test evaluates total recall, delayed recall, percent of retention, and recognition. Higher score means better outcome. Longitudinal data of neurocognitive function will be analyzed using a linear mixed model and toxicity indicators will be assessed using a chi-square or exact test. |
Up to 2 years
|
|
Neurocognitive function - Grooved Pegboard Test
Prazo: Up to 2 years
|
Will be measured by the Grooved Pegboard Test. Scale 0 seconds to time of completion in minutes and seconds. Higher time to completion means worse outcome. Longitudinal data of neurocognitive function will be analyzed using a linear mixed model and toxicity indicators will be assessed using a chi-square or exact test. |
Up to 2 years
|
|
Neurocognitive function - Trail Making Test
Prazo: Up to 2 years
|
Will be measured by the Trail Making Test. Scale Part A: 0 seconds to 100 seconds (time of greater than 100 seconds discontinues the test. Scale Part B: 0 seconds to 300 seconds (time of greater than 300 seconds discontinues the test. Number of errors recorded. Higher time to completion and greater number of errors means worse outcome. Longitudinal data of neurocognitive function will be analyzed using a linear mixed model and toxicity indicators will be assessed using a chi-square or exact test. |
Up to 2 years
|
|
Neurocognitive function - Brief Test of Attention
Prazo: Up to 2 years
|
Will be measured by the Trail Making Test. Scale 0 to 20 points. Higher score mean better outcome. Longitudinal data of neurocognitive function will be analyzed using a linear mixed model and toxicity indicators will be assessed using a chi-square or exact test. |
Up to 2 years
|
|
Quality of life (QOL) - European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30-item
Prazo: Up to 2 years
|
Will be measured by the European Organization for Research and Treatment of Cancer Quality of Life Core 30-item (EORTC QLQ-C30) questionnaire. Scale 30 to 126 points. Higher score means worse outcome. Longitudinal data of QOL will be analyzed using a linear mixed model and toxicity indicators will be assessed using a chi-square or exact test. |
Up to 2 years
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Prakash Ambady, MD, Providence Health & Services
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- PHS-OB-PCNSL-01
- ML29496 (Outro identificador: Genentech, Inc.)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .